Despite Pain Drug’s Mid-Stage Miss, Adynxx Plans a Larger Phase 3 Test

An Adynxx pain drug has failed to meet the main goal of a mid-stage study, but the company instead points to results in a subset of patients that it says are strong enough to justify advancing the treatment into a larger Phase 3 clinical trial.